Prefer Sun Pharma, says Neeraj Deewan

Neeraj Deewan of Quantum Securities told CNBC-TV18, "Sun Pharmaceutical Industries - the kind of results that came, with the pending merger with Ranbaxy, the kind of scale they will have together that is one which though we don’t cover too many pharma names and anyways they are not cheap also after the run up but Sun Pharma stands out. I think that can be looked at even after the run up."

Sun Pharmaceutical Industries ended at Rs 926.25, up Rs 6.85, or 0.75 percent on the BSE.